DDInter1610 DDInter822
Rivastigmine is a parasympathomimetic or cholinergic agent for the treatment of mild to moderate dementia of the Alzheimer's type. Rivastigmine is a cholinesterase inhibitor that inhibits both butyrylcholinesterase and acetylcholinesterase.
Glasdegib, also known as PF-04449913, is a small-molecule hedgehog signaling inhibitor selected under the group of benzimidazoles. In early research, benzimidazoles attracted large interest as they represented a class of inhibitors with low molecular weight, potent inhibitory activity, and lacking unstable functionality. The great lipophilicity of this group of compounds brought interest to further modification. This analysis concluded that the presence of p-cyano ureas presented good physicochemical and pharmacokinetic properties from which glasdegib was developed. Glasdegib was developed by Pfizer Inc and approved on November 21, 2018 by the FDA for the treatment of Acute Myeloid Leukemia (AML). Glasdegib targets cancerous cells by inhibiting the sonic hedgehog receptor smoothened (SMO), a transmembrane protein involved in the Hedgehog (Hh) signaling cascade. Aberrant of Hh signaling is one of the main pathophysiologies of AML, with observed overexpression or constitutive activation of SMO.[A258498,A258503] Although the efficacy of glasdegib monotherapy is limited, the landmark Phase 2 Bright AML 1003 trial showed a superior overall survival and complete response when glasdegib is combined with low dose cytarabine. Currently, the current gold standard of AML in older patients is still venetoclax with hypomethylation agents, new clinical combinations of glasdegib are being tested in hope of replacing venetoclax due to glasdegib's more favorable side effects profile.
Rivastigmine {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Sulfamethoxazole
Sulfamethoxazole {u} may cause a minor interaction that can limit clinical effects when taken with {v} Glasdegib
Rivastigmine {u} (Compound) causes {v} (Side Effect) Purpura
Purpura {u} (Side Effect) is caused by {v} (Compound) Sulfamethoxazole
Sulfamethoxazole {u} may cause a minor interaction that can limit clinical effects when taken with {v} Glasdegib
Rivastigmine {u} (Compound) causes {v} (Side Effect) Purpura
Purpura {u} (Side Effect) is caused by {v} (Compound) Lomefloxacin
Lomefloxacin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Glasdegib
Rivastigmine {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Morphine
Morphine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Glasdegib
Rivastigmine {u} (Compound) causes {v} (Side Effect) Flat affect
Flat affect {u} (Side Effect) is caused by {v} (Compound) Boceprevir
Boceprevir {u} may lead to a major life threatening interaction when taken with {v} Glasdegib
Rivastigmine {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Bedaquiline
Bedaquiline {u} may lead to a major life threatening interaction when taken with {v} Glasdegib
Rivastigmine {u} (Compound) resembles {v} (Compound) Pyridostigmine
Pyridostigmine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Fingolimod
Fingolimod {u} may lead to a major life threatening interaction when taken with {v} Glasdegib
Rivastigmine {u} (Compound) resembles {v} (Compound) Tapentadol
Tapentadol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sodium sulfate
Sodium sulfate {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Glasdegib
Rivastigmine {u} (Compound) resembles {v} (Compound) Pyridostigmine
Pyridostigmine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Brigatinib
Brigatinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Glasdegib
Rivastigmine {u} (Compound) resembles {v} (Compound) Tapentadol
Tapentadol {u} may lead to a major life threatening interaction when taken with {v} Morphine
Morphine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Glasdegib
Rivastigmine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Sulfamethoxazole (Compound) and Sulfamethoxazole may cause a minor interaction that can limit clinical effects when taken with Glasdegib
Rivastigmine (Compound) causes Purpura (Side Effect) and Purpura (Side Effect) is caused by Sulfamethoxazole (Compound) and Sulfamethoxazole may cause a minor interaction that can limit clinical effects when taken with Glasdegib
Rivastigmine (Compound) causes Purpura (Side Effect) and Purpura (Side Effect) is caused by Lomefloxacin (Compound) and Lomefloxacin may cause a moderate interaction that could exacerbate diseases when taken with Glasdegib
Rivastigmine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Morphine (Compound) and Morphine may cause a moderate interaction that could exacerbate diseases when taken with Glasdegib
Rivastigmine (Compound) causes Flat affect (Side Effect) and Flat affect (Side Effect) is caused by Boceprevir (Compound) and Boceprevir may lead to a major life threatening interaction when taken with Glasdegib
Rivastigmine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Bedaquiline (Compound) and Bedaquiline may lead to a major life threatening interaction when taken with Glasdegib
Rivastigmine (Compound) resembles Pyridostigmine (Compound) and Pyridostigmine may cause a moderate interaction that could exacerbate diseases when taken with Fingolimod and Fingolimod may lead to a major life threatening interaction when taken with Glasdegib
Rivastigmine (Compound) resembles Tapentadol (Compound) and Tapentadol may cause a moderate interaction that could exacerbate diseases when taken with Sodium sulfate and Sodium sulfate may cause a moderate interaction that could exacerbate diseases when taken with Glasdegib
Rivastigmine (Compound) resembles Pyridostigmine (Compound) and Pyridostigmine may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib and Brigatinib may cause a moderate interaction that could exacerbate diseases when taken with Glasdegib
Rivastigmine (Compound) resembles Tapentadol (Compound) and Tapentadol may lead to a major life threatening interaction when taken with Morphine and Morphine may cause a moderate interaction that could exacerbate diseases when taken with Glasdegib